je.st
news
Arena - Flatness In Scripts Will Impact The Equity
2015-05-09 04:01:10| Biotech - Topix.net
Arena Pharmaceuticals has seen sales of the anti-obesity drug Belviq flatten out over the past few weeks while competitor Contrave from Orexigen continues to close the gap. Over the last two months Belviq sales have gained less than 1% and have moved from about 14,100 scripts in the first week in March to about 14,800 scripts at the close of April.
Tags: the
impact
equity
scripts
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||